ScanSource (SCSC) Q4 2026 earnings review
Top-Line Acceleration Meets a Transformational Acquisition
ScanSource finished FY26 with a decisive top-line beat, as Q4 Net Sales accelerated to 17.3% YoY growth ($953M), completely reversing the contractions seen early in the fiscal year. Hardware demand roared back, driving EPS up 41% to $1.24. However, the aggressive growth required heavy working capital, pushing Q4 Free Cash Flow into negative territory. Looking forward, management announced the $220.5M all-cash acquisition of MicroAge, a move designed to permanently shift the company toward higher-margin IT and AI services. While FY27 organic guidance is solid (6-10% sales growth), investors must weigh the upcoming balance sheet leverage against the promised margin accretion.
🐂 Bull Case
The core Specialty Technology Solutions (STS) segment surged 17.6% YoY. The destocking and delayed large deals that plagued the first half of FY26 have clearly broken loose, accelerating top-line momentum into FY27.
The $220.5M acquisition of MicroAge brings established Microsoft, CrowdStrike, and AI solutions to the channel. It is expected to be immediately accretive to Gross Margins, Adjusted EBITDA, and EPS, accelerating the 'Converged Solutions' strategy.
🐻 Bear Case
Despite record Q4 EPS, Free Cash Flow reversed to a negative $4.8M. Accounts Receivable ballooned to $769M (from $635M a year ago), indicating the rapid sales growth is trapping cash.
Consolidated Gross Margin fell 35 basis points YoY to 12.6%. The high-growth STS segment saw operating margins compress heavily as favorable vendor mix and pricing dynamics from early FY26 faded.
⚖️ Verdict: ⚪
Cautiously Optimistic. The revenue acceleration is undeniable and the MicroAge acquisition is strategically sound. However, compressed gross margins, negative Q4 cash flow, and persistent weakness in Brazil demand tight operational execution as the company takes on new debt.
Key Themes
MicroAge Acquisition to Reshape the Margin Profile
ScanSource is spending $220.5M in cash to acquire MicroAge, a massive pivot toward IT solutions, managed services, and AI. This addresses the long-standing strategic goal to increase the mix of high-margin software/services. The deal is expected to close in Q1 FY27 and will immediately lever up ScanSource's 'zero net debt' balance sheet, likely drawing heavily on their credit facility.
Specialty Technology Solutions (STS) Accelerates Sharply
STS net sales grew 17.6% YoY to $927M, accelerating from 9% growth in Q3 and an outright decline in Q1. Broad-based hardware demand in North America drove the beat. This validates management's prior claims that large deals were merely delayed, not lost, earlier in the year.
Gross Margin Compression Amidst Revenue Boom
A key contradiction to the bullish top-line story: as revenue accelerated, margins compressed. STS gross margin dropped sequentially from 11.0% in Q3 to 10.1% in Q4. Consolidated gross margin dropped 35 basis points YoY to 12.6%. The volume rebound came at the expense of pricing power and favorable vendor mix.
Brazil Operations are Collapsing
The Brazil segment is reversing violently. Reported sales dropped 21.6% YoY, but adjusting for currency, organic sales plummeted 30.2% YoY to just $47.6M. Once hailed by the CEO as a model for recurring cloud revenue, the region has become a severe structural drag on the consolidated entity.
Intelisys Remains Trapped in Single-Digit Growth
Despite massive internal restructuring (the 'Converged Communications' pivot) designed to re-accelerate the cloud and connectivity business, Intelisys & Advisory grew a stable but uninspiring 7.2% YoY in Q4. Furthermore, GAAP operating margin for the segment dropped nearly 400 basis points sequentially, highlighting the heavy SG&A investments yielding limited top-line acceleration.
Aggressive Capital Returns Completed
ScanSource leveraged its previously pristine balance sheet to aggressively buy back stock while shares were under pressure. The company executed $97.9M in share repurchases in FY26. With the MicroAge acquisition absorbing $220.5M in cash in early FY27, the pace of buybacks is likely to decelerate significantly.
Other KPIs
Stable. Recurring revenue as a percentage of total gross profit was 31.5% in Q4, functionally flat compared to 31.6% a year ago. While the FY26 full-year average ticked up to 33.7%, the Q4 stall indicates the organic path to their '50% long-term goal' remains steep—hence the MicroAge acquisition.
Reversing. Free Cash Flow flipped negative in Q4, down from $68.9M in Q3 and $5.1M in Q4 FY25. The explosive 17% revenue growth drove a massive $133M full-year build in Accounts Receivable, tying up cash on the balance sheet and contradicting the strong 'quality of earnings' narrative.
Guidance
Decelerating compared to Q4's 17.3% exit rate, but represents a stable, healthy organic growth profile over the full year. Crucially, this guidance excludes the pending MicroAge acquisition, meaning reported growth will be significantly higher.
Accelerating sequentially on an annual basis. At the midpoint ($161.5M), this implies ~6.6% YoY growth over FY26's $151.5M. This aligns with the revenue growth target, implying management expects gross margins to stabilize and operational leverage to hold.
Decelerating. Down from the $113.8M generated in FY26. Management is telegraphing that the working capital required to fund 6-10% organic sales growth will continue to act as a headwind to cash conversion in the coming year.
Key Questions
MicroAge Integration and Leverage
You are spending $220.5M in cash to acquire MicroAge. Post-close, what is your expected net debt leverage ratio, and how does this alter your appetite for the remaining $179M share repurchase authorization?
STS Margin Compression
STS segment gross margins fell to 10.1% this quarter. How much of this was related to competitive pricing pressure versus unfavorable vendor mix, and does the FY27 guidance assume margins stay at this lower run-rate?
Brazil's Path Forward
Organic sales in Brazil fell 30% YoY. Is this strictly macroeconomic, or are we losing structural market share? At what point do you consider strategic alternatives for this geography?
Intelisys 'Converged' Reorganization
We are now several months into the 'Converged Communications' restructuring for Intelisys. When will the stated goal of 'accelerating new orders' visibly translate into double-digit revenue growth for the I&A segment?